Oncology landscape stays hot for dealmakers

Intense competition for dealmaking in oncology “shows no sign of abating.” That’s the key takeaway from recent analysis developed by Jamie Munro and Helen Dowden, of Clarivate Analytics. Their article, “Oncology dealmaking trends”, was featured in the Biopharma Dealmakers supplement to Nature Biotechnology and Nature Reviews: Drug Discovery. Munro, global practice leader, portfolio and licensing, […]

Immuno-oncology spotlight on diverse therapeutic classes

Immune checkpoint inhibitors, such as the multi-billion-dollar drugs Keytruda and Opdivo, have dominated the immuno-oncology landscape in recent years (see Figure 1), but are not the only classes on the market or in development. T-cell engager therapeutics, oncolytic virus therapy and adoptive T-cell therapies were among the promising technologies covered at the fourth annual Immuno-Oncology […]

Drug development challenge: Managing CMC submissions

In the era of Breakthrough Therapy and Fast Track drug designations, chemistry, manufacturing and controls (CMC) submissions can cause delays to bring a drug to market, said Drew Barlow, vice president, regulatory affairs at Syner-G Pharma Consulting.  Companies need to provide enough information to satisfy the regulatory requirements while recognizing that providing too much information early will […]

Immune-related and genetic disorder products drive Cortellis Drugs to Watch 2019

Seven drugs are set to enter the market in 2019 and achieve blockbuster status by 2023, according to Cortellis Drugs to Watch 2019, from Clarivate Analytics. Therapies targeting diseases characterized by genetic disorder and/or excessive immune response (including autoimmunity) dominate the list, with six agents out of the seven, and a strong showing by orphan […]

Life sciences innovation: What is it? How do we track it? How do we get more?

Most people working in biopharmaceutical R&D would agree that innovation is important. But, what is innovation? Googling “What is innovation?” returns more than a billion hits. Focusing on the top search result from the Google dictionary doesn’t add further insight: “the action or process of innovating.” However, in producing The Life Sciences Innovation Report: A […]

Indivior’s Sublocade contributing to transformation of opioid dependence market

The 2018 Drugs to Watch report, the annual industry forecast and analysis from Clarivate Analytics published in March, forecast 12 new drugs to enter the market in 2018 and achieve blockbuster sales of $1 billion or more by 2022. In a follow-up series we have reviewed the status and landscape of each expected blockbuster with the […]

Roche’s Hemlibra: Market expansion approved, but safety an initial concern?

The annual industry forecast and analysis report Drugs to Watch from Clarivate Analytics was published in March 2018, detailing the pharma industry’s expected blockbuster launches for 2018. The report was led by Roche/Chugai’s hemophilia drug Hemlibra (emicizumab), for which analysts had very big expectations, and consensus forecasts stood at $4.002 billion for 2022 at the […]

Predictive analytics yield smarter pharma portfolio decisions

Collecting competitive data isn’t the problem; most biopharma companies are drowning in it. But making sense of the data, using it to predict likely shifts in the competitive landscape and drive decisions can be a challenge. While forecasting drug timelines and success rates are critical to inform investment and R&D decisions, the standard approach has […]

Erleada gains first-mover advantage in CRPC

The 2018 edition of Drugs to Watch, the annual industry forecast and analysis from Clarivate Analytics, predicted approval and market entry of Johnson & Johnson’s Erleada (apalutamide), the first FDA-approved treatment for non-metastatic castration-resistant prostate cancer (CRPC).1,2 This approval came two months ahead of its April 2018 PDUFA date and only four months after its […]

Generics companies, responding to tough times, steer towards higher-risk portfolio strategies

These are tough times financially and strategically for many generics companies, particularly in the U.S., the world’s largest pharmaceutical market. Manufacturers are experiencing falling net prices driven by customer consolidation and increasing competition, coupled with a lack of operational flexibility and a landscape of new product opportunities significantly different from those of the past. Additionally, […]